Roivant unveils new subsidiary on deal with Ligand

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant

Read the full 237 word article

User Sign In